Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Fennec Pharmaceuticals Inc./ 10-K

Annual Report · 10-K

Fennec Pharmaceuticals Inc.

Annual Report

Filed Mar 29, 2023Accepted Mar 29, 2023, 5:22 PM EDTCIK 1211583Accession 0001558370-23-004948
View company →Permanent SEC source ↗
Share

Company context

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSIÒ.

Current securities

FENCNASDAQ · EQUITY · CurrentFRXTSX · EQUITY · Current
Historical securities (2)
ADRXFOTC · WARRANT · Historical · closed Mar 31, 2016FENCFOTC · EQUITY · Historical · closed Sep 13, 2017

Recent company filings

  1. SCHEDULE 13G/A - filed by HIRSCHMAN ORIN regarding FENNEC PHARMACEUTICALS INC.Oct 19, 2026
  2. Other EventsSep 17, 2026
  3. 144 filingSep 15, 2026
  4. SCHEDULE 13G/A - filed by Solas Capital Management, LLC regarding FENNEC PHARMACEUTICALS INC.Aug 14, 2026
  5. 10-Q filingAug 13, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.